Phase II, Single Arm, Single Institution Clinical Trial Of Docetaxel and Doxorubicin In Combination With Local Administration Of AD5CMV-P53 (RPR/INGN 201) In Locally Advanced Breast Cancer (LABC).

Trial Profile

Phase II, Single Arm, Single Institution Clinical Trial Of Docetaxel and Doxorubicin In Combination With Local Administration Of AD5CMV-P53 (RPR/INGN 201) In Locally Advanced Breast Cancer (LABC).

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2009

At a glance

  • Drugs Contusugene ladenovec; Docetaxel; Doxorubicin
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Introgen Therapeutics
  • Most Recent Events

    • 08 Jun 2009 New source identified and integrated (University of Texas M.D. Anderson Cancer Center).
    • 08 Jun 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top